
ImmunoGen Inc is a biotechnology business based in the US. ImmunoGen shares (IMGN) are listed on the NASDAQ and all prices are listed in US Dollars. ImmunoGen employs 106 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in ImmunoGen
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IMGN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

ImmunoGen stock price (NASDAQ: IMGN)
Use our graph to track the performance of IMGN stocks over time.ImmunoGen shares at a glance
Latest market close | $4.61 |
---|---|
52-week range | $3.10 - $7.77 |
50-day moving average | $4.09 |
200-day moving average | $5.40 |
Wall St. target price | $12.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.59 |
Buy ImmunoGen shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy ImmunoGen stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
ImmunoGen price performance over time
Historical closes compared with the close of $4.61 from 2022-07-01
1 week (2022-06-24) | 6.96% |
---|---|
1 month (2022-06-03) | 24.59% |
3 months (2022-03-30) | N/A |
6 months (2022-01-03) | -38.37% |
1 year (2021-07-02) | -28.30% |
---|---|
2 years (2020-07-02) | -5.53% |
3 years (2019-07-03) | 104.89% |
5 years (2017-07-03) | 6.81 |
ImmunoGen financials
Revenue TTM | $92.2 million |
---|---|
Gross profit TTM | $-81,261,000 |
Return on assets TTM | -17.97% |
Return on equity TTM | -64.6% |
Profit margin | -140.3% |
Book value | $1.39 |
Market capitalisation | $1 billion |
TTM: trailing 12 months
ImmunoGen share dividends
We're not expecting ImmunoGen to pay a dividend over the next 12 months.
ImmunoGen share price volatility
Over the last 12 months, ImmunoGen's shares have ranged in value from as little as $3.1 up to $7.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmunoGen's is 1.1729. This would suggest that ImmunoGen's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
ImmunoGen overview
ImmunoGen, Inc. , a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc. ; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc. ; CytomX Therapeutics, Inc.
ImmunoGen in the news
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline
We're Keeping An Eye On ImmunoGen's (NASDAQ:IMGN) Cash Burn Rate
Frequently asked questions
What percentage of ImmunoGen is owned by insiders or institutions?Currently 0.433% of ImmunoGen shares are held by insiders and 94.297% by institutions. How many people work for ImmunoGen?
Latest data suggests 106 work at ImmunoGen. When does the fiscal year end for ImmunoGen?
ImmunoGen's fiscal year ends in December. Where is ImmunoGen based?
ImmunoGen's address is: 830 Winter Street, Waltham, MA, United States, 02451-1477 What is ImmunoGen's ISIN number?
ImmunoGen's international securities identification number is: US45253H1014 What is ImmunoGen's CUSIP number?
ImmunoGen's Committee on Uniform Securities Identification Procedures number is: 45253H101
More guides on Finder
-
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
-
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
-
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert